Sutro Biopharma (NASDAQ:STRO) Given New $8.00 Price Target at Wedbush

Sutro Biopharma (NASDAQ:STRO) had its price objective lowered by Wedbush from $12.00 to $8.00 in a report published on Tuesday morning, MarketBeat reports. Wedbush currently has an outperform rating on the stock. Wedbush also issued estimates for Sutro Biopharma’s Q1 2025 earnings at ($0.83) EPS, Q2 2025 earnings at ($0.88) EPS, Q3 2025 earnings at ($0.74) EPS and Q4 2025 earnings at ($0.76) EPS.

STRO has been the topic of a number of other reports. HC Wainwright reduced their target price on shares of Sutro Biopharma from $16.00 to $12.00 and set a buy rating on the stock in a research report on Tuesday. JMP Securities restated a market outperform rating and set a $17.00 target price on shares of Sutro Biopharma in a research note on Tuesday. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Sutro Biopharma has a consensus rating of Buy and an average price target of $13.71.

Sutro Biopharma Stock Up 17.9 %

Shares of STRO opened at $4.93 on Tuesday. The firm has a fifty day simple moving average of $4.47 and a two-hundred day simple moving average of $3.77. Sutro Biopharma has a twelve month low of $2.01 and a twelve month high of $6.11. The stock has a market capitalization of $300.48 million, a P/E ratio of -2.77 and a beta of 0.95.

Insider Buying and Selling at Sutro Biopharma

In other news, insider Nicki Vasquez sold 12,185 shares of the company’s stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $5.00, for a total transaction of $60,925.00. Following the sale, the insider now directly owns 12,803 shares in the company, valued at approximately $64,015. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 6.90% of the stock is owned by company insiders.

Institutional Trading of Sutro Biopharma

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC boosted its holdings in shares of Sutro Biopharma by 14,125.8% in the fourth quarter. Nisa Investment Advisors LLC now owns 8,820 shares of the company’s stock valued at $38,000 after purchasing an additional 8,758 shares during the period. Wells Fargo & Company MN lifted its holdings in shares of Sutro Biopharma by 331.7% during the 4th quarter. Wells Fargo & Company MN now owns 5,690 shares of the company’s stock valued at $46,000 after purchasing an additional 4,372 shares during the last quarter. Point72 Hong Kong Ltd purchased a new stake in shares of Sutro Biopharma during the second quarter worth about $46,000. Tower Research Capital LLC TRC increased its stake in Sutro Biopharma by 342.3% during the 3rd quarter. Tower Research Capital LLC TRC now owns 15,128 shares of the company’s stock valued at $52,000 after purchasing an additional 11,708 shares in the last quarter. Finally, Ergoteles LLC purchased a new stake in Sutro Biopharma during the 2nd quarter valued at about $54,000. 96.99% of the stock is owned by hedge funds and other institutional investors.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. It develops site-specific and novel-format antibody drug conjugates (ADC) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. The company's product candidates include STRO-001, an ADC directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials.